Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease
Year: 2024
Type: article
Study design: Observational Study
Abstract: Background Adherence is critical in patients with Alzheimer's disease (AD) in order to achieve optimal benefit from therapy. However, patient compliance with the treatment remains a challenge. Objective To evaluate, in a real-world clinical setting, caregiver preference and treatment compliance with twice-weekly versus daily transdermal rivastigmine patch in mild-to-moderate AD. Methods 92 patients who had been treated with daily rivastigmine patch for at least six months prior to switching to twice-weekly patch were evaluated. The change in therapeutic regimen was decided by the treating physician in accordance with standard practice. Caregivers’ satisfaction with daily rivastigmine patch was assessed at study entry. Caregiver's preference and satisfaction with twice-weekly patch as well as patient compliance were evaluated at weeks 12 and 24 using the Alzheimer's Disease Caregiver Preference Questionnaire. Results A significantly higher proportion of caregivers expressed a preference for the twice-weekly patch over the daily patch ( p < 0.001), and this preference was found to be associated with ease of use ( p < 0.001), ease of following the schedule ( p < 0.001), and ease of compliance ( p < 0.001). Furthermore, caregivers were more satisfied with the twice-weekly patch ( p < 0.0001). At 24 weeks, patient compliance was significantly better with the twice-weekly patch than with the daily patch ( p = 0.002). Caregiver burden significantly improved at the end of the treatment ( p = 0.003). No serious adverse events were reported. Conclusions The twice-weekly rivastigmine patch offers a convenient and straightforward dosing regimen for caregivers, with potential to enhance adherence with treatment in AD patients without causing serious adverse events.
Source: Journal of Alzheimer s Disease
Authors: José María García-Alberca, Paz De La Guía, Esther Gris, Silvia Mendoza, María López De La Rica, José Antonio López-Trigo, Rosa López-Mongil, Teresa García-López, Raquel López-García, Teresa Rodríguez Del Rey, Javier Gay-Puente, Jesús García-Castro, Federico Casales, Xavier Morato, Mercè Boada, Gemma González-Velasco, José Manuel Marín-Carmona, Nora Inés Páez, María León, Rosario Carrillejo, Francisca Rius, Miguel Ángel Barbancho, José Pablo Lara, Encarnación Blanco-Reina
Language: English
Subfield: Family Practice
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Esteve Pharmaceuticals
OpenAlex ID: W4404122219